Table 1.
Baseline Characteristics (FAS)
| Variable | SOC (n = 21) n (%) |
SOC + ALECSAT (n = 40) n (%) |
Total (N = 61) N (%) |
|---|---|---|---|
| Age | |||
| Median, years (range) | 62.0 (44–69) | 55.5 (38–69) | 57.0 (38–69) |
| Mean, years (SD) | 59.9 (±7.3) | 55.2 (±9.0)* | 56.8 (± 8.6) |
| Gender | |||
| Female | 9 (42.9) | 16 (40.0) | 25 (41.0) |
| Male | 12 (57.1) | 24 (60.0) | 36 (59.0) |
| Performance statusa | |||
| 0 | 10 (47.6) | 19 (47.5) | 29 (47.5) |
| 1 | 10 (47.6) | 19 (47.5) | 29 (47.5) |
| 2 | 1 (4.8) | 2 (5.0) | 3 (4.9) |
| Type of surgery | |||
| Complete resection | 10 (47.6) | 17 (42.5) | 27 (44.3) |
| Partial resection | 8 (38.1) | 21 (52.5) | 29 (47.5) |
| Biopsy | 3 (14.3) | 2 (5.0) | 5 (8.2) |
| Tumor locationb | |||
| Frontal | 5 (23.8) | 13 (32.5) | 18 (29.5) |
| Temporal | 11 (52.4) | 17 (42.5) | 28 (45.9) |
| Parietal | 5 (23.8) | 7 (17.5) | 12 (19.7) |
| Occipital | 1 (4.8) | 6 (15.0) | 7 (11.5) |
| Multifocalc | 0 (0) | 1 (2.5) | 1 (1.6) |
| Tumor characteristics | |||
| IDH1wt | 21 (100) | 39 (97.5) | 60 (98.4) |
| IDH1mut | 0 (0) | 1 (2.5) | 1 (1.6) |
| MGMT status | |||
| Unmethylated | 7 (33.3) | 28 (70.0) | 35 (57.4) |
| Methylated | 14 (66.7) | 12 (30.0)** | 26 (42.6) |
| Use of steroids at baseline | |||
| Yes | 10 (47.6) | 10 (25.0) | 20 (32.8) |
| No | 11 (52.4) | 30 (75.0) | 41 (67.2) |
| Median time from surgery to start of oncological treatmentd (days and range) | 35 (23–43) | 31 (22–42) | 32 (22–43) |
aPerformance status, according to Eastern Cooperative Oncology Group/WHO.
bFive patients had unifocal tumors engaging more than 1 lobe.
cMultifocal tumor, defined as at least 2 separate contrast-enhancing lesions.
dWaiting time from surgery to start of radiotherapy and TMZ.
*P = .046, **P = .013.